CRMDCormedix Inc.
Cormedix Inc. (CRMD) develops and commercializes therapies for the treatment of invasive fungal infections and neuroinflammation. The company’s next catalyst is Oct 15, 2026 — Phase 3 Trial Initiation (Neuro), which will test the readiness of its neuro-inflammation platform and the strength of its clinical pipeline. The event will also highlight the company’s ability to execute on its Phase 3 trial design and regulatory strategy.
- Revenue in 2026 reached $308.18M, with a net margin of 62.6% (TTM).
- Net income hit $192.98M, and diluted EPS was 0.29, reflecting strong profitability.
- Shareholders’ equity stands at $405.31M, with a solid capital structure.
The Read
7% on average around anticipated developments, with a notable 45.
The schedule
- Sun4Oct
CRMD Stock Soared 18% Today – Here’s What Fueled CorMedix’s Triple-Digit Q1 Rev…
- Thu15Oct
The initiation tests whether the company can execute a large-scale trial, which is critical for regulatory approval and revenue potential. This differs from the last trial initiation, which faced delays in patient recruitment.
- Wed11Nov
The earnings release will test the company's ability to meet revenue and guidance expectations, particularly in light of the recent clinical trial progress. This differs from the last earnings report, which saw a positive surprise due to better-than-expected sales.
- Tue15Dec
The scrutiny tests the company's ability to secure favorable reimbursement rates, which is critical for long-term profitability. This differs from the last policy review, which resulted in a neutral outcome due to uncertainty in the regulatory environment.
- Sun14Feb
The earnings release will test the company's ability to meet revenue and guidance expectations, particularly in light of the recent clinical trial progress. This differs from the last earnings report, which saw a positive surprise due to better-than-expected sales.
- Tue13Apr
The participation in the virtual event tests the company's ability to generate investor interest and secure follow-up meetings. This differs from the last event, which saw limited engagement due to market volatility.
- Thu13May
The participation in the upcoming events tests the company's ability to generate investor interest and secure follow-up meetings. This differs from the last event, which saw limited engagement due to market volatility.
- Thu13May
The earnings release will test the company's ability to meet revenue and guidance expectations, particularly in light of the recent clinical trial progress. This differs from the last earnings report, which saw a positive surprise due to better-than-expected sales.
- Thu12Aug
The earnings release will test the company's ability to meet revenue and guidance expectations, particularly in light of the recent clinical trial progress. This differs from the last earnings report, which saw a positive surprise due to better-than-expected sales.
Past
- Thu13Aug
Actual outcome: Bull · $8.52 at outcome
CRMD reported in-line EPS of 0.33, matching estimates, and provided positive forward guidance on revenue growth and operating leverage. The stock rallied 4.7% as investors focused on the potential for scaling the Melinta portfolio integration and improved operational efficiency, despite the lack of an earnings beat.
CRMD will report Q2 earnings on August 13. Focus will be on validating the massive $127.4M Q1 revenue base and seeing if operating leverage scales alongside the Melinta portfolio integration.
- Wed1Jul
Actual outcome: Bear · $7.87 at outcome
Despite CorMedix posting surging DefenCath-led revenue and expanding its portfolio with Melinta assets like Rezzayo, the stock declined 7.1% by the outcome date. The market reacted negatively to emerging reimbursement changes and execution risks, which raised concerns about the company's long-term earnings durability and overshadowed the strong initial growth.
Anticipated market developments regarding competitor pricing strategies or alternative lock solutions aiming to undercut DefenCath's market share.
- Thu14May
Actual outcome: Bull · $7.93 at outcome
CorMedix met Q1 EPS estimates exactly at $0.18, validating its commercial revenue base and financial stability. Additionally, the company reported positive topline results from its Phase 3 ReSPECT trial for REZZAYO, successfully meeting the primary endpoint for fungal-free survival. This combination of steady earnings and major clinical success in a $2 billion market drove shares well above the $7.30 bull target.
Q1 2026 earnings will test whether CorMedix can sustain its new commercial revenue base off a lower starting point around $5.8; confirmation of durable sales growth and margin discipline could lift the stock toward $7.30, while signs that 2025’s revenue step-up was front-loaded or one-off in nature could drag shares toward $7.30.
- Wed15Apr
Actual outcome: Bull · $8.05 at outcome
The anticipated dilutive equity raise or debt refinancing did not materialize, removing a major overhang on the stock. Instead, management presented its clinical and commercial plans at the Needham Virtual Healthcare Conference, which reassured investors and drove an 11.3% rally past the bull target despite earlier bearish reports concerning DefenCath revenue.
Investors are watching for a potential equity raise or refinancing around $7.08 as CorMedix balances rapid revenue growth with funding needs for new trials and broader commercialization; a modestly accretive structure could keep shares near $7.4, while a deeply discounted deal or leverage overhang could reset the stock toward $7.40.
- Thu5Mar
Actual outcome: Bull · $6.79 at outcome
CorMedix reported Q4 EPS of $0.18, exactly meeting analyst estimates and validating the initial full-quarter sales data for Defencath. These in-line earnings results, coupled with news of increased institutional accumulation from Assenagon Asset Management, reassured investors and drove a steady rally in the stock toward the bull target.
Initial full-quarter sales data for Defencath and management guidance for FY 2026 adoption rates in outpatient dialysis settings.
